Haemophilia

Papers
(The H4-Index of Haemophilia is 21. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
AHP Oral Abstracts66
Effectiveness of therapeutic exercise and cognitive‐behavioural therapy combined protocol on functionality, pain and joint health in people with haemophilia: Secondary analysis of a controlled trial40
13th BIC International Conference37
How to assess, detect, and manage joint involvement in the era of transformational therapies: Role of point‐of‐care ultrasound35
Recommendations for Psychosocial Support during Gene Therapy: Results From an EAHAD Interdisciplinary Roundtable34
New Treatment in Haemophilia: Challenges, Controversies and Uncertainties33
The importance and evolution of bleeding disorder registries31
Into a brave new world: Haemophilia A & von Willebrand Disease Surgery with novel therapies30
Haemophilia B, severe childhood obesity and other extra‐haematological features associated with similar 4Mb‐deletions on Xq27: Clinical findings, molecular insights and literature update29
The detrimental effects of iron to the joint; aggravation by inflammation28
The effects of emicizumab on in vitro coagulation and fibrinolysis parameters in patients with disseminated intravascular coagulation with and without addition of anti‐FVIII antibody28
A systematic review of adeno‐associated virus gene therapy clinical trials for HIV – A potential solution for patients with haemophilia and HIV?28
Health‐related quality of life among adults with haemophilia in China: A comparison with age‐matched general population27
CCS_Book of abstracts27
Competence and Confidence: An Evaluation of Physiotherapists' Knowledge and Self‐Perception About Physical Activity and Exercise in Patients With Haemophilia27
Targeting higher factor VIII levels for prophylaxis in haemophilia A: a narrative review27
Developing a Two‐Sided Decision Box to Facilitate Shared Decision‐Making for Switching From Conventional to Pharmacokinetic‐Tailored Prophylaxis in Haemophilia24
The legacy of haemophilia: Memories and reflections from three survivors24
Issue Information23
Reinvestigation of unidentified causative variants in FXI‐deficient patients: Focus on gene segment deletions22
Test–retest reliability of a mobile application of the patient reported outcomes burdens and experiences (PROBE) study21
Wearable activity trackers in young people with haemophilia: What needs to be considered?21
Initial von Willebrand factor antigen values in adolescent females predict future values21
0.15289187431335